Viral Vectors and Plasmid DNA Manufacturing Market Revenue 2024 to 2034
Viral Vectors and Plasmid DNA Manufacturing Market Revenue 2024 to 2034
The viral vectors and plasmid DNA manufacturing market stood at USD 6.3 Bn in 2024 and will reach USD 26.7 Bn by 2034, growing at 15.59% CAGR, driven by gene therapy and vaccines.
Report ID: 10529
|
Format: Databook
|
Published: August 2025
|
Delivery: Immediate
Download Sample
Customisation Request
Revenue,
USD 6.26 Bn
Forecast Year,
USD 26.65 Bn
CAGR, 2025 -
15.59%
Report Coverage
Worldwide
Reviewed By
Aditi Shivarkar
Reviewed By
Aman Singh
Viral Vectors and Plasmid DNA Manufacturing Market Size Analysis
Viral Vectors and Plasmid DNA Manufacturing Market Size By Product 2024 to 2034 (USD )
| Product | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AAV | 1.57 | 1.80 | 2.06 | 2.37 | 2.72 | 3.13 | 3.59 | 4.12 | 4.73 | 5.43 | 6.24 |
| Adenovirus | 0.75 | 0.87 | 1.01 | 1.17 | 1.36 | 1.58 | 1.83 | 2.12 | 2.46 | 2.86 | 3.32 |
| Lentivirus | 1.00 | 1.17 | 1.37 | 1.60 | 1.86 | 2.18 | 2.54 | 2.97 | 3.46 | 4.04 | 4.72 |
| Retrovirus | 0.44 | 0.50 | 0.57 | 0.65 | 0.74 | 0.84 | 0.95 | 1.08 | 1.23 | 1.40 | 1.58 |
| HSV | 0.31 | 0.35 | 0.40 | 0.45 | 0.51 | 0.58 | 0.65 | 0.73 | 0.82 | 0.92 | 1.04 |
| Plasmid DNA | 2.19 | 2.54 | 2.95 | 3.43 | 3.98 | 4.62 | 5.37 | 6.23 | 7.24 | 8.41 | 9.76 |
Viral Vectors and Plasmid DNA Manufacturing Market Size By Workflow 2024 to 2034 (USD )
| Workflow | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Upstream Processing | 2.82 | 3.26 | 3.76 | 4.35 | 5.03 | 5.81 | 6.71 | 7.76 | 8.97 | 10.36 | 11.98 |
| Downstream Processing | 2.50 | 2.89 | 3.35 | 3.87 | 4.47 | 5.17 | 5.97 | 6.91 | 7.98 | 9.23 | 10.67 |
| Fill-Finish | 0.94 | 1.09 | 1.26 | 1.45 | 1.68 | 1.94 | 2.24 | 2.59 | 3.00 | 3.47 | 4.01 |
Viral Vectors and Plasmid DNA Manufacturing Market Size By Application 2024 to 2034 (USD )
| Application | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gene Therapy | 3.13 | 3.62 | 4.18 | 4.83 | 5.58 | 6.45 | 7.46 | 8.62 | 9.96 | 11.51 | 13.30 |
| Vaccinology | 1.25 | 1.44 | 1.65 | 1.90 | 2.18 | 2.50 | 2.87 | 3.30 | 3.79 | 4.35 | 5.00 |
| Cell Therapy | 1.57 | 1.82 | 2.11 | 2.44 | 2.84 | 3.29 | 3.82 | 4.43 | 5.14 | 5.96 | 6.91 |
| Others | 0.31 | 0.37 | 0.43 | 0.50 | 0.58 | 0.67 | 0.79 | 0.92 | 1.07 | 1.24 | 1.45 |
Viral Vectors and Plasmid DNA Manufacturing Market Size By End-use 2024 to 2034 (USD )
| End-use | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharma & Biotech | 3.44 | 3.99 | 4.62 | 5.35 | 6.20 | 7.19 | 8.33 | 9.65 | 11.18 | 12.95 | 15.01 |
| CDMO/CMO | 2.19 | 2.53 | 2.92 | 3.37 | 3.89 | 4.49 | 5.18 | 5.98 | 6.90 | 7.96 | 9.18 |
| Academic/Research | 0.63 | 0.72 | 0.82 | 0.94 | 1.08 | 1.24 | 1.43 | 1.63 | 1.87 | 2.15 | 2.46 |
Viral Vectors and Plasmid DNA Manufacturing Market Size By Region 2024 to 2034 (USD )
| Region | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | 2.50 | 2.87 | 3.30 | 3.79 | 4.35 | 4.99 | 5.73 | 6.58 | 7.55 | 8.66 | 9.94 |
| Europe | 1.88 | 2.18 | 2.52 | 2.92 | 3.39 | 3.93 | 4.55 | 5.28 | 6.12 | 7.09 | 8.22 |
| Asia Pacific | 1.38 | 1.59 | 1.84 | 2.13 | 2.46 | 2.84 | 3.28 | 3.80 | 4.39 | 5.07 | 5.86 |
| Latin America | 0.25 | 0.29 | 0.33 | 0.37 | 0.43 | 0.49 | 0.56 | 0.64 | 0.73 | 0.83 | 0.95 |
| Middle East & Africa | 0.25 | 0.31 | 0.37 | 0.45 | 0.55 | 0.67 | 0.81 | 0.97 | 1.17 | 1.40 | 1.68 |
Viral Vectors and Plasmid DNA Manufacturing Market
Viral Vectors and Plasmid DNA Manufacturing Market
Proceed To Buy
Proceed To CheckoutMake Every Move Strategic. Get Insights, Fully Customized
- On-Demand Metrics & KPIs
- Industry-Specific Dashboards
- Quick Turnaround, No Compromises
Quick Contact
- NA : +1 804 441 9344
- APAC : +91 9356 9282 04
- EU : +44 7782 560 738
- sales@precedenceresearch.com
